CHMP
-
Diabetes Drug Receives Positive Opinion from CHMP
AstraZeneca and Bristol-Myers Squibb have announced that their marketing authorisation application for Onglyza (saxagliptin) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP). This is for the treatment…
CHMP | 09 July 2009
-
CHMP Delays Decision to Approve Zevtera
Janssen-Cilag has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has decided to delay the European Commission decision process on Zevtera (ceftobiprole medocaril) pending completion of a …
CHMP | 02 March 2009
-
First melatonergic antidepressant receives EU CHMP positive opinion
The first melatonergic antidepressant Valdoxan/Thymanax (agomelatine) has received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for its use in the treatment of adult patients w…
CHMP | 26 November 2008
